TABLE 2—
Fee-for-Service Drug Spending on Sofosbuvir, Utilization Criteria, and Medicaid Expansion Decisions, by State: United States, 2014
State | FFS Drug Spending Accounted for by Sofosbuvir, % | Medicaid Expansiona | Strict Clinical Criteria | Strict Behavioral Criteria | Strict Administrative Criteria |
Maryland | 0.08 | Y | N | Y | Y |
Wisconsin | 0.18 | N | N | Y | Y |
New Hampshire | 0.25 | N | N | N | Y |
Alaska | 0.27 | N | Y | Y | N |
West Virginia | 0.28 | Y | Y | Y | Y |
Iowa | 0.29 | Y | N | Y | Y |
Oregon | 0.30 | Y | N | Y | Y |
Pennsylvania | 0.35 | N | N | Y | Y |
Virginiab | 0.47 | N | N | Y | Y |
Kentucky | 0.66 | Y | Y | Y | Y |
Rhode Island | 0.67 | Y | N | Y | Y |
Delaware | 0.71 | Y | Y | Y | N |
Mississippi | 0.73 | N | N | Y | Y |
District of Columbia | 0.76 | Y | Y | Y | Y |
Arkansas | 0.79 | N | N | N | N |
Idaho | 0.88 | N | Y | N | Y |
Colorado | 1.11 | Y | N | Y | Y |
Washington | 1.19 | Y | Y | Y | Y |
California | 1.20 | Y | Y | Y | Y |
Arizona | 1.25 | Y | Y | N | Y |
Nebraska | 1.25 | N | N | Y | N |
Louisiana | 1.34 | N | N | Y | Y |
Utah | 1.41 | N | N | N | N |
Ohio | 1.64 | Y | N | Y | Y |
Alabama | 1.77 | N | N | Y | N |
South Dakota | 1.87 | N | N | Y | Y |
Illinois | 1.92 | Y | N | Y | Y |
Vermont | 1.94 | Y | N | Y | N |
Florida | 2.05 | N | Y | Y | Y |
North Carolina | 2.10 | N | N | Y | N |
Wyoming | 2.52 | N | N | Y | N |
Missouri | 2.77 | N | N | Y | N |
Maine | 2.84 | N | N | N | Y |
Minnesota | 3.06 | Y | N | N | N |
Montana | 3.21 | Y | N | Y | Y |
Indiana | 3.29 | N | N | N | Y |
New York | 3.63 | Y | Y | N | Y |
Oklahoma | 3.73 | N | N | Y | Y |
Tennessee | 4.44 | N | Y | Y | Y |
Nevadac | 5.26 | Y | N | N | N |
Massachusetts | 5.76 | Y | N | N | N |
Connecticut | 6.68 | Y | N | N | Y |
Note. FFS = fee for service.
Y indicates expansion over all 4 quarters of 2014 (excludes states with expansion beginning in 2014 or after).
Calculated from 3 quarters of data (data from 2nd quarter excluded as erroneous entry).
Did not use prior authorization criteria.